Abstract | The management of chronic myeloid leukaemia (CML) has changed extensively over the past 15 years. Prior to the development of targeted therapies and in the absence of allogeneic haematopoetic stem-cell transplantation (HSCT), the median survival was 5-7 years. HSCT was quickly established as the standard of care for eligible patients through the 1980s and 1990s, when considerable advances were made in the optimization of conditioning regimens and supportive care. Exploiting a deeper understanding of the molecular basis of CML, the development of tyrosine kinase inhibitors (TKIs) in the late 1990s revolutionized the management of the disease. TKIs offer the prospect of long-term disease control with a simple oral therapy, and are the first-line treatment in the 21 st century. The majority of patients treated with TKIs achieve excellent responses with sustained treatment, and some even continue to have undetectable or exceptionally low level disease upon TKI withdrawal; however, for an almost equal number of patients, an adequate response cannot be achieved with any of the currently available TKIs. For those patients who fail to respond adequately to TKIs, HSCT offers the best prospect of long-term survival.
Chronic myeloid leukaemia (CML) is a clonal haemato poetic stemcell disorder that is characterized by the presence of the oncogenic BCR-ABL1 gene fusion. The reciprocal translocation of the long arms of chromo some 9 and chromosome 22 was named the 'Philadelphia chromosome' following its place of discovery in the early 1960s 1 . The translocation positions ABL1 next to the breakpoint cluster region (BCR) gene and, depending on the exact breakpoint location, the fused BCR-ABL1 oncogene is translated into a protein of 185-210 kDa; there are three clinically important variants of this pro tein, p190, p210 and p230, with the p210 variant being typical of CML 2, 3 . The mutant Bcr-Abl1 protein is a dysregulated nonreceptor tyrosine kinase that phos phorylates a variety of substrate proteins, resulting in loss of cellcycle control with consequential increased proliferation, loss of stromal adhesion and resistance to apoptosis.
The disease course of CML is triphasic 4, 5 (TABLE 1) .
The majority of patients present in the relatively stable chronic phase, which, if left untreated, progresses through a period of increasing genomic instability to accelerated phase, and then on to blast crisis, which is invariably fatal. In contrast to the p190 Bcrabl1 variant, which typically drives lymphoblastic lineage in acute lymphoblastic leukaemia (ALL) 6 , the p210 Bcrabl1 variant, typical of CML, drives a true stem cell disorder demonstrated by the fact that the final transformation in CML can result in myeloblastic (50%) or lymphoblastic (25%) phenotypes, with the remaining 25% comprising biphenotypic or undifferentiated blasts 2, 3 . The early treatment approaches in chronic phase CML, such as arsenic, busulphan, hydroxycarbamide or interferon, were effective in controlling the symptoms associated with the disease, but were unable to signifi cantly alter its natural progression. These thera pies con ferred little advantage in terms of survival, increasing the median overall survival from 4-5 years to 6-7 years using even the mosteffective combination regimens that included αinterferon and cytosine arabinoside 7 . During the 1980s, allogeneic haematopoetic stemcell transplantation (HSCT) became the only treatment capable of curing CML. Despite the high mortality that was attributed to transplant procedures in the early days, the introduction of HSCT had a consider able impact on median survival, and resulted in long term cure for many patients. Early registry followup data from transplants performed in the 1980s and early 1990s indicated 20year overall survival of 40%, 20% and 10% for chronic phase, accelerated phase and blast crisis, respectively, with transplant related mortality (TRM) approaching 40% 8, 9 . Subsequent improvements in the conditioning regimens and supportive care during the late 1990s and into the 21 st century have hugely improved those outcomes, with a 2010 regis try report demonstrating 3year overall survival for goodrisk patients in excess of 90% with 100 day TRM of only 8% for those transplanted in chronic phase 10 , figures that are closely mirrored by individual centres including our own 11 . For several decades, HSCT remained the gold stand ard treatment for eligible patients, until the development of tyrosine kinase inhibitors (TKIs) in the late 1990s. These agents (of which imatinib was the first) block the ATPbinding pocket of the ABL1 domain, and thereby inhibit phosphorylation. The specificity of imatinib and the subsequent secondgeneration (dasatinib, nilotinib and bosutinib) and thirdgeneration (ponatinib) drugs for Abl1 tyrosine kinase results in the preferential death of cells harbouring the BCR-ABL1 mutation. The intro duction of these drugs dramatically altered CML care and offered the prospect of longterm disease control with an oral therapy. Longterm followup from the semi nal studies continues to report excellent outcomes, with an estimated 8year overall survival in the order of 85% 12 . Indeed, results derived from patients entered into a series of firstline studies of TKIs at a single centre suggest that the life expectancy of patients treated with TKIs is now comparable to that of the normal US population 13 . TKIs are capable of inducing and maintaining a deep remission in the majority of patients, but the two most divergent groups -that is, the best and poorest responders -now pose new questions. In a relatively small group of patients with the deepest responses (those in whom BCR-ABL1 transcripts cannot be detected for at least 2 years), remission can be main tained following treatment cessation 14, 15 . One of these studies speculated that up to one third of patients might be eligible for a trial of treatment withdrawal, and up to 40% of those might remain in remission following cessation 15 . However, a similar proportion of patients (between 10-15%) will fail to achieve an adequate response to multiple TKIs because of either resistance or intolerance. So, although TKIs have undoubtedly revolutionized the management of CML, we must not forget that CML remains a fatal disease for those who do not respond to these agents, and this is the group for whom HSCT offers a wellestablished, feasible alter native. Equally, however, HSCT is not without compli cations: the nonmalignant longterm complications of HSCT ranging from those that are directly related to the conditioning, such as cata racts, infertility and radiationinduced tissue damage, to those resulting from chronic graftversushost disease (GVHD) 16 and its treatments, can impact negatively on quality of life 17 and life expectancy 18 . Striking the balance between the poor survival associated with a lack of response to TKIs and the potential longterm complications of HSCT is therefore difficult. In this Review, we focus on the current role of allogeneic HSCT in CML, drawing on lessons learned from the extensive transplant experi ence over the past three decades; we aim to provide an update on the current literature and offer our own opinions to guide this decision.
Assessing treatment response
The European Leukaemia Network (ELN) has estab lished criteria to guide the management of CML by defining response categories and timescales by which certain predefined responses should be achieved (TABLE 2) , allowing the identification of optimal, warn ing and failing groups of patients 5, 19 . These guidelines provide a framework for the management of this disease by defining the responses that are expected at certain time points after starting treatment, and highlight those in whom a change in TKI may be required. However, individ ual patient circumstances such a compliance, comorbidities and patterns of responses, might mod ify this recommended management. Early ELN guide lines used complete haematological response, complete cytogenetic response and major molecular response as milestones
. However, their most recent rec ommendations also incorporate the finding by several groups that the inability of a treatment to achieve a 10fold reduction in tumour load by 3 months, as indi cated by the presence of >10% levels of BCR-ABL1 tran scripts using realtime, quantitative reverse transcription polymerase chain reaction (qRTPCR), is associated with inferior longterm survival 20, 21 . This recommenda tion had been included as an addition to the existing criteria, but in practice BCRABL1 transcripts of less than 10% at 3 months are the best predictor of optimal response at later timepoints.
Key lessons learned from HSCT in CML Over the past three decades, CML has been one of the commonest indications for HSCT. The large numbers of transplants and pioneering work of some key CML physicians has led to the generation of a strong evidence base upon which much of our cur rent HSCT practice is based. The lessons learned have been used to improve the safety and efficacy of HSCT for CML, but are applicable to HSCT for almost all haematological malignancies.
The graft versus leukaemia effect
Allogeneic transplantation for CML was first reported in 1979 (REF. 22 ) using syngeneic donors, and was quickly followed in 1982 by reports of encouraging outcomes using sibling donors 23 . The restricted avail ability of compatible sibling donors soon led to the
Key points
• While TKIs have revolutionised the treatment of CML, allogeneic HSCT remains the only treatment capable of curing CML • For the 10-15% of patients with chronic phase CML unable to achieve an adequate response with a tolerable dose of TKI, allogeneic HSCT offers a feasible alternative strategy • Early assessment strategies should be used to identify those destined to fail to respond to TKIs, allowing rapid transition through multiple TKIs and on to, if necessary, HSCT before disease progression occurs • The mechanisms of disease control from TKI and HSCT are independent, therefore, poor response to TKI does not per se predict poor response to HSCT • Allogeneic HSCT remains the standard of care for patients with accelerated phase or blast crisis CML use of HLAmatched volunteerunrelated donors 24 , although early attempts at volunteerunrelated donor HSCT were hampered by high rates of transplant related mortality 25 . The introduction of Tcell deple tion partially circumvented this problem in the short term by reducing the incidence and severity of acute GVHD, but it rapidly became apparent that this ben efit came at the expense of a higher risk of relapse 26 . This direct evidence for the role of the graftversus leukaemia (GVL) effect, which revealed the sensitiv ity of the disease to Tcelldependent disease immune control, led the pioneers to try to manipulate the GVL effect with the use of infusions of lymphocytes from the original donors (donor lymphocyte infusions) to restore durable remissions 27 . The development of escalating dose regi mens largely abrogated the risk of concomi tant acute GVHD 28, 29 and these regimens, which are deemed safe for sibling, volunteerunrelated and even mismatched donor use 30 , remain the mainstay of post HSCT relapse management in CML, as well as many other GVLsensitive malignancies.
The clinical impact of induced GVL responses led to the realization that an alloimmune mechanism, rather than conditioning chemoradiotherapy, is largely respon sible for disease control in CML, at least in the case of patients with chronic phase disease. This finding there fore paved the way for the development of reduced intensity regimens to extend access to HSCT to those who would be deemed unfit for conventional myelo ablative conditioning 31, 32 . Interestingly, although these regimens remain useful, particularly in combination with early preemptive donor lymphocyte infusion 33 , and for those in whom comorbidity would otherwise preclude transplantation, myeloablative conditioning remains the preferred approach for the majority of suitable patients. This observation probably reflects the fact that myeloablative conditioning remains extremely well tolerated in patients with chronic phase CML com pared to those with other malignancies, and that the reducedintensity approach is associated with higher rates of chronic GVHD, complicating the use of donor lymphocyte infusion, which is commonly required for disease eradication in this context.
Transplant and disease risk stratification
The use of HSCT for CML provided the first model of risk assessment strategies within transplanta tion. The European Society for Blood and Marrow Transplantation (EBMT) developed a scoring system for risk assessment in the 1990s when CML was the most common indication for allogeneic HSCT 34 . This system, developed using data obtained from more than 3,000 patients with CML, is based on five main risk factors: donor type, stage of disease at time of trans plantation, age of recipient, sex of donor and recipient, and time from diagnosis to transplantation
. The cumulative score, which was highly predict ive for leukaemia free survival, overall survival and transplant related mortality in the initial study, was subsequently validated in more than 56,000 transplants by the EBMT 35 , and remains the most powerful predictor of transplant outcome across haematological malignan cies. Those with the lowest risk score (0) have a TRM of 20%, and 5year overall survival of 72%, whereas those with the highest score (6) have a TRM of 72% with a 5year overall survival of 22%. Interesting, a key observation in pretransplant optimization was that debulking the disease in chronic phase, either by splenectomy or splenic irradiation before transplantation, did not confer a survival advan tage nor a reduced risk of relapse 36 . However, progres sion of disease beyond chronic phase had a profoundly detrimental effect on outcome, with transplantation in frank blast crisis being frequently futile. These findings were observed nearly 30 years ago, but their implications remain equally pertinent today, in the TKI era.
Minimal residual disease monitoring
The monitoring of minimal residual disease (MRD) was pioneered in transplant for treating CML. Detection of BCRABL1 transcripts in peripheral blood by PCR assays was developed to detect disease relapse following HSCT. The early methodologies were qualitative, but systems that enable serial quantitative measurement were quickly developed 37 . These exquisitely sensitive techniques are now the cornerstone of disease and response monitoring in CML, but they were originally developed to reliably define molecular relapse following HSCT 37, 38 .
Indications for HSCT in the TKI era
The advisability and timing of HSCT depends on the phase of CML that the patient is in. The most clearcut indication for HSCT is disease beyond chronic phase and, for this reason, we start with blast crisis.
Blast crisis
Blast crisis is considered to be the consequence of genomic instability resulting from DNA damage caused by persistent BCR-ABL1 activity, and is often character ized by the accumulation of additional karyo typic abnormalities. The impact of TKIs has been the least striking in this group of patients, with only a mod est rise in median survival following their widespread use (3-4 months in the preTKI era to 7-11 months follow ing their use 39 ), and the benefit has usually been shortlived. HSCT offers the only prospect of long term survival for patients in this group. Two key points are important when considering HSCT for patients presenting in, or progressing to, blast crisis. First, the best outcomes are achieved by returning patients to chronic phase before HSCT, because the outcome for those patients who receive HSCT in frank blast crisis is dismal (less than 10% longterm survival) 40 . This return to chronic phase (termed, chronic phase 2) can be achieved using TKIs alone 41 , by the use of conven tional acute leukaemiatype combination chemotherapy alone 42 , or by using both approaches simultaneously [43] [44] [45] . The evidence base for an improved outcome using combined chemotherapy and a TKI is limited, but the need to restore chronic phase is urgent, and therefore giving maximum therapy ab initio is not unreasonable. Second, an intriguing observation is that the most fre quent cause of death posttransplant is not, in fact, pro gressive disease but, rather, transplantrelated mortality. These patients suffer from extremely high nonrelapse mortality with registry data from the TKI era reporting 46% 1year mortality if transplanted in blast crisis 46 , which improves to 33% if a second chronic phase is achieved before transplant. The reason for this TRM is unclear: although the contribution of pretransplant chemo therapy, drug toxicity or atypical/fungal infec tions resulting from prolonged immunosuppression might partially explain the high TRM when compar ing outcomes to those patients who received HSCT in first chronic phase, these factors cannot explain the differences observed between HSCT for patients with CML in blast crisis and those with acute leukaemias, who have experienced equally intense conditioning and transplant regimens. Even highrisk patients with acute myeloid leukaemia who undergo HSCT during their first complete remission (with frequently compar able demographs and induction regimen character istics to patients with CML in blast crisis) have a 3year transplant related mortality rate of 10-20% 47, 48 . Ultimately, however, despite the TRM, HSCT should be offered to all eligible patients with CML in blast cri sis for whom a suitable donor exists, as it is the only realistic prospect of longterm survival. 
Accelerated phase disease
The definition of accelerated phase has always been more subjective than those of chronic phase and blast crisis, which has resulted in the term 'acceleration' describing a heterogeneous population; some patients are in the early stages of transformation, whereas others have progressed further, to the brink of blast crisis. This issue is con founded by the fact that the definitions were established in the preTKI era, during which the loss of response to therapy would constitute acceleration, whereas now the loss of a cytogenetic or molecular response to imatinib would simply trigger a switch to a secondgeneration agent, often with good effect. Such heterogeneity makes the group difficult to con sider as a single entity. For those on the brink of transfor mation to blast crisis, HSCT undoubtedly offers the best chance of longterm survival. However, a TKIbased regi men might suffice for those patients who are in the early stages of the transition from chronic phase to accelerated phase. Consequently, attempts have been made to fur ther riskstratify patients in accelerated phase 49 (TABLE 3) .
Jiang et al. 49 suggested that lowrisk patients -those with no risk factors according to this proposed stratification -gain no advantage from HCST over treatment with imatinib alone (6year overall survival rate 81% versus 100%). However, the outcome for highrisk patients (those with two or three risk factors) who did not receive HSCT was extremely poor, yet eminently salvageable, with HSCT (5year overall survival 18% versus 100%). In another study, patients with accelerated phase CML treated with imatinib or secondgeneration TKIs alone showed a remarkable 3year overall survival of 87% and 95%, respectively 50 ; however, this cohort would appear to represent patients in the early stages of transformation, indicating that this strategy might not be suitable for all patients in accelerated phase.
In practical terms, most clinicians will initiate therapy with a TKI and carefully monitor the molecular response. Patients at low risk might continue treatment with TKIs alone if an 'optimal response' has been achieved; how ever, this approach comes with the caveat that the defi nition of an 'optimal response' has been validated only in patients with chronic phase disease. Few clinicians would withhold HSCT from those patients with highrisk accelerated phase disease.
Chronic phase disease
The decision whether or not to carry out HSCT in patients with chronic phase CML is undoubtedly con troversial and complex. Frontline therapy with imatinib induces a major molecular response in ~60% of patients with chronic phase disease 12 . Dasatinib and nilotinib in the frontline setting are even more effective, achieving a major molecular response in ~75% of patients at 4year followup 51, 52 . However, the rates of treatment discontinu ation either from loss/lack of control (using the crit eria in TABLE 2, or those with persisting rising BCR-ABL transcripts) or intolerable side effects are high: 45% of patients have stopped imatinib after 8 years of treat ment 12 , and 32% and 31-34% have stopped dasatinib 51 and nilotinib 52 , respectively, after 4 years of treatment. Of those patients who switched to a secondgeneration TKI following imatinib cessation, 70% have discontinued their first choice secondgeneration TKI after 6 years 53, 54 . Clear and reproducible data for second, third or fourth line treatment with bosutinib or ponatinib are still emer ging, but similar failure/discontinuation rates should be expected. Irrespective of the firstline treatment choice, these data suggest that a sizeable minority (~10-15%) of patients will be unable to obtain an optimal response to a tolerable TKI treatment, and will require an alternative strategy -of which HSCT is one (FIG. 1) .
Turning to HSCT from TKIs
No biomarkers currently exist to reliably predict a poor response to TKI at diagnosis of CML. However, data suggesting that a group of poorrisk patients can be Each of the risk criteria scores are combined to obtain a total score that correlates with the 5-year outcome probabilities as shown. *EBMT developed in CML, but is broadly applicable across haematological malignancies. EBMT, European Society for Blood and Marrow Transplantation; LFS, leukaemia-free survival; OS, overall survival; TRM, treatment-related mortality. identified as soon as 3 months after the start of any TKI treatment 20, 21 are beginning to change our approach to management, with changes in drug therapy occurring sooner in an effort to prevent early disease progression. With five licenced TKIs, the tendency is to try multi ple lines of therapy before referring the patient for transplant. Unfortunately, the delay imposed by such a strategy will inevitably result in disease progression in some patients who might otherwise have benefited from HSCT; for that reason we discuss the rationale behind streamlining the approach.
Nature Reviews
Worldwide, the majority of newly diagnosed chronic phase patients commence therapy with imatinib. If a patient fails to respond, loses an established response or experiences unacceptable toxicity, it would be routine practice to try one or other of the secondgeneration drugs, dasatinib, nilotinib or bosutinib. In some cir cumstances, the actual choice might be guided by the presence of a kinasedomain mutation or certain comor bidities, but in the majority of cases, any of these drugs can be used as their efficacy is equivalent. The dilemma emerges if the patient is resistant and/or intolerant to the secondline therapy. The efficacy of a thirdline second generation drug (that is, switching between dasatinib, nilotinib and bosutinib) is limited: reports of local or regional series as well as a systematic review indicate the achievement of a complete cytogenetic response in 20-30% of patients; the durability of these responses is less clear [55] [56] [57] . Furthermore, it is difficult to determine any features that might predict a response to the third line agent, although at least two reports have shown an associ ation with prior cytogenetic response on the first line and/or secondline therapy 52, 53, 58 . Intuitively, the feel ing is that a patient who has demonstrated resistance to two lines of therapy with no obvious explanation, such as noncompliance or the development of a kinasedomain mutation, is less likely to be responsive to a thirdline agent of similar efficacy. Furthermore, in the situation of multiple intolerances and side effects, particularly those involving haematological toxicity, the use of a thirdline agent is likely to result in the develop ment of further intolerance and side effects, even if the patient shows sensitivity to the third drug. Similar arguments against the use of a further second generation agent can be made for a patient failing firstline therapy with dasatinib or nilotinib.
The thirdgeneration drug, ponatinib, has shown impressive efficacy as a second, third and fourthline therapy 59 ; once again, those patients who are likely to respond well to ponatinib can be identified after 3 months of treatment. It is entirely reasonable, therefore, to sug gest that a patient eligible for transplant should ideally transition through imatinib to a secondgeneration agent (but not rotate through all three) and then to ponatinib, or from firstline dasatinib or nilotinib to ponatinib, in order to consider a transplant, if necessary, as early as possible in the disease course. In practice, this pathway will be influenced by drug availability, the presence of mutations, comorbidities and the nature of any intoler ance shown, but the overall aim should be to avoid the risk of disease progression. We therefore advocate that patients who fail firstline therapy should be referred for donor identification to avoid any subsequent delay if HSCT becomes necessary.
Does prior treatment with TKIs affect HSCT?
To inform patient choice regarding the risks and bene fits of HSCT, we need to be confident that existing data, accumulated in the preTKI era, remain valid in current Note: these data are derived from a single study 49 .
Figure 1 | Overall response rates to TKIs in chronic phase disease. a | Imatinib. Approximately 60% of patients treated with frontline imatinib will respond. Of those, up to two thirds may achieve a deep enough response to qualify for a trial of treatments (a minimum of 2 years of undetectable BCR-ABL transcripts) and up to 15% of the original group may maintain a prolonged remission off treatment. For the 40% who do not respond, around 50% will respond to a second-generation TKI (dasatinib, nilotinib or bosutinib). Of the 50% who require a third-generation drug, only half will respond, meaning 10-15% of patients will not achieve an adequate response with any TKI. b | Secondgeneration TKIs. While the initial response rates to frontline second-generation drugs is slightly higher at 70-80%, only half of the 20-30% who do not respond will subsequently respond to a third-generation drug, meaning that again 10-15% of patients require an alternative strategy to TKI, of which HSCT is a viable option. HSCT, haematopoetic stem-cell transplantation; TKI, tyrosine kinase inhibitor. practice. Several early studies seeking to validate existing data supported the notion that the use of TKIs does not negatively impact on subsequent transplant outcome [60] [61] [62] ; however, these studies were often small, and confounded by the fact that the control (nonTKI treated) group were historical comparators, not contemporaneously trans planted patients. Several authors have subsequently tried to address the issue of HSCT in the TKI era (summar ized in TABLE 4) . Perhaps the most systematic approach, how ever, comes from the reanalysis of EBMT data carried out in 2014 (REF. 63 ). Milojkovic et al. 63 addressed the validity of the original EBMT risk score by reviewing the outcome of more than 5,500 patients who had received HSCT for CML between 2000 and 2011 (REF. 63 ), which covers the period of transition to TKI use. Similar 5year overall survival and progressionfree survival (PFS) rates were observed in transplant recipients previously treated with TKIs compared to TKInaive transplant recipients (overall survival 59% versus 61% and PFS 42% versus 46%). Interestingly, although a time from diagnosis to transplantation of more than 12 months remained an independent predictor of poor outcome in the TKI naive group, this value was no longer predictive in those treated with TKIs. This discrepancy is difficult to fully understand, but it is tempting to speculate that even in those patients who showed signs of resistance and, par ticularly in those who were intolerant to TKIs, some still benefited from a certain degree of disease control with their TKI.
Few studies have directly compared HSCT to TKI treatment; however, the German CML VI study reported 56 patients who received HSCT in chronic phase either through patient choice or owing to failure to respond to imatinib. In a matched pair analysis, 106 patients not undergoing HSCT were compared to 56 who under went HSCT, and similar overall survivals were demon strated (96% versus 92%, respectively) 10 . Perhaps more importantly, reinforcing the idea that prolonged prior use of imatinib does not negatively impact on trans plant outcome, patients electing to undergo HSCT follow ing a brief initial treatment with imatinib (n = 19) had a survival rate similar to those who proceeded to Most recently used TKI. AP, accelerated phase; BC, blast crisis; BM, bone marrow; CI, comorbidity index; CMR, complete molecular remission; CP, chronic phase; DFS, disease-free survival; EBMT, European Society for Blood and Marrow Transplantation; EFS, event-free survival; HSCT, haematopoietic stem-cell transplant; LFS, leukaemia-free survival; MAC, myeloablative conditioning; NR, not reported; OS, overall survival; PB, peripheral blood; PFS, progression-free survival; RIC, reduced-intensity conditioning; TKI, tyrosine kinase inhibitor; TRM, transplant-related mortality. *Reported for combined myeloablative and reduced-intensity conditioning groups, with no significant difference between MAC and RIC. AP, accelerated phase; AraC, cytosine arabinoside; ATG, antithymocyte globulin; BC, blast crisis; Bu, busulfan; CI, comorbidity index; CP, chronic phase; cyclo, cyclophosphamide; DBM, dibromomannitol; Flu, fludarabine; GVHD, graft-versus-host disease; LFS, leukaemia-free survival; MAC, myeloablative conditioning; melph, melphalan; NR, not reported; NRM, non-relapse mortality; RIC, reduced-intensity conditioning; TBI, total body irradiation. 1 9 9 0 1 9 9 1 1 9 9 2 1 9 9 3 1 9 9 4 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 CML early CML advanced Nature Reviews | Clinical Oncology transplantation following imatinib failure (n = 37) (3year overall survival of 88% and 94%, respectively). Predictably, the 3year overall survival for those trans planted in accelerated phase disease was significantly lower, at 59%.
Additional considerations
For many young, healthy patients, the prospect of life long medication with frequent monitoring and clini cal review might compare less favourably to an intense period of treatment undergoing an HSCT, despite excel lent longterm results with TKIs. Moreover, whereas access to TKIs is relatively easy in countries of high economic status, this is not the case in many develop ing countries. Even in developed countries, a case can be made that HSCT is more costeffective than lifelong TKI therapy, particularly in children, adolescence and young adults. One relatively small study from 2006 compared the cost of HSCT to imatinib, and concluded that treatment with imatinib was 25% more expensive than reducedintensity conditioning HSCT over the first 2 years of treatment 64 . The cumulative influences on these treatments of falling costs of TKIs as patents expire and the normalization of lifespan, make pre dictions about relative costeffectiveness in current practice difficult.
Toxicity, intolerance and compliance
When considering HSCT as an alternative to TKIs owing to toxicity, intolerance, or compliance every attempt must have been made to manage the side effects of the responsible drug. Although many of the toxicities observed early after treatment initiation, such as rash, fluid retention, nausea, diarrhoea and other gastrointestinal upset, respond well to temporary treat ment interruption or dose reduction, some do not and treatment cessation is therefore necessary. Recurrent haematological toxicity, even after dose reduction, can render continued TKI treatment problematic. More serious and lifethreatening drug specific toxicities (such as pleural effusions, pulmonary hypertension and cardi ac dysfunction) have been described after treat ment with both secondgeneration and thirdgenera tion drugs 59, 65, 66 , which have also required cessation of the causative drug. In these cases, a strong argument can be made for recommending HSCT.
Just as the adherence to treatment with a TKI is a critical factor for achieving a molecular response in CML 67 , so, too, is the adherence to posttransplant regi mens to minimize the complications of HSCT such as GVHD, infection and viral reactivation. Although it might seem logical to assume that those who came to transplant because of known or unknown poor com pliance with TKI therapy will be poorly compliant with posttransplant prophylaxis, this cannot necessarily be assumed. The behaviour of compliance is complex 68 and, often, poor compliance is driven by side effects or treatment fatigue that is induced by prolonged treatment durations. Therefore, although poor com pliance with TKI therapy should alert the transplant physician to the possibility of poor compliance post HSCT, it should not preclude the use of HSCT if it is otherwise indicated.
The intricacies of HSCT in the TKI era Conditioning regimens Early regimens of chemoradiotherapy given to condition the marrow for stemcell transplants were fully myelo ablative. Typically, these regimens consisted of total body irradiation with additional chemotherapy -frequently cyclophosphamide. The realization that longterm remission is dependent on the GVL effect led to the suggestion that transplantation regimens could be made safer by reducing the intensity of the condition ing and by reinforcing the GVL effect with preemptive donor lymphocyte infusions 3133 . Although no pro spective randomized trials comparing myeloablative with reducedintensity conditioning have been carried out, case series reports and registry data suggest that reduced intensity conditioning is a feasible strategy to increase accessibility to transplant for patients who would other wise be ineligible (TABLE 5) . In particular, reducedintensity regimens extend the age at which HSCT can be safely undertaken. The previously dis cussed higher relapse rates associated with reduced intensity protocols, however, deem them unsuitable for high risk patients. Therefore, myeloablative conditioning remains the standard of care for those patients who are capable of tolerating them, with the majority of centres frequently continuing to employ total body irradiation and cyclophosphamidebased protocols.
T-cell depletion
The depletion of T cells, either by negatively selecting donor Tcells in the graft in vitro or by treating the The number of transplants for advanced stage disease (second (or higher) chronic phase, accelerated phase and blast crisis) has remained stable. Early, defined as first chronic phase and advanced, defined as accelerated phase, second (or higher) chronic phase and blast crisis. Data kindly provided by the EBMT transplant activity office. recipient with monoclonal antibodies (alemtuzumab) or antithymocyte globulin in vivo, are wellestablished strategies to decrease the risk of GVHD, but comes at the expense of the GVL effect. Socié and colleagues 69 demonstrated some dissociation of the risk of relapse from the risk of acute GVHD using rabbit anti thymocyte globulin to achieve Tcell depletion in recipi ents of unrelated transplant following myeloablation. Although these data support the idea that future strat egies might be able to reduce the risk of GVHD without impacting on the risk of relapse, at present the decision to use Tcell depletion or not is based on a risk-benefit assessment of the risk of acute GVHD versus the risk of relapse. While Tcell depletion might be advantageous for a mismatched recipient undergoing HSCT in chronic phase, there is little or no benefit for sibling HSCT in a second chronic phase where the risks of acute GVHD would be inherently low, and the risk of relapse signifi cantly higher. On the basis of a lack of strong evidence of whom and how to Tcell deplete, these decisions will typically depend on the treating physician's preference and the institution.
Source of stem cells
Historically, stem cells derived from bone marrow have been used for HSCT, but the advent of clinical grade growth factors now enables stem cells to be harvested from peripheral blood. For reasons of faster engraft ment and donor preference, peripheral blood stem cells (PBSCs) have now largely replaced bone marrow derived stem cells as the stem cell source of choice. However, the use of PBSCs for those patients in first chronic phase CML is associated with higher rates of nonrelapserelated mortality and, consequently, lower rates of survival 70 . Furthermore, in a recent ran domized controlled trial comparing the use of PBSCs to bonemarrowderived stem cells which included, but was not limited to patients with CML, higher rates of chronic GVHD were observed using stem cells from the peripheral blood compared with those derived from bone marrow (53% versus 41%) 71 . Although this study revealed no impact on overall survival or PFS, the find ings are particularly pertinent to CML patients. Up to 50% of patients receiving a transplant for chronic phase CML will subsequently develop molecular relapse, necessitating donor lymphocyte infusions to restore remission, particularly if reducedintensity condition ing regimens are used 64 ; active chronic GVHD precludes the use of donor lymphocyte infusions, thereby hamper ing the management of relapse. Therefore, every effort should be made to reduce the risk of chronic GVHD to enable the subsequent use of donor lymphocyte infu sion if required, not to mention to reduce the burden of morbidity associated with chronic GVHD likely to be responsible for the higher rates for nonrelapse mortality seen with the use of PBSC in first chronic phase CML transplant recipients. Although a cautious approach would therefore favour the use of bonemarrowderived stem cells in patients with first chronic phase CML, more often than not the final choice of the harvest method lies with the donor.
Management of relapse
For those patients who receive HSCT in chronic phase, relapse -if it occurs -will most likely be at a low level and initially detectable only by qRTPCR. Longstanding criteria exist to define relapse following HSCT, and these criteria are highly predictive of progressive dis ease 37, 72 . Following relapse, immune modulation with cessation of ongoing immunosuppression followed by donor lymphocyte infusion, if necessary, constitutes the most powerful strategy for restoring remission in the majority of patients with molecular relapse 27, 28, 73 . Adherence to escalating dose regimens (starting with 1 × 10 6 Tcells per kg in volunteerunrelated donors, and with 1 × 10 7 Tcells per kg in sibling recipients, rising in a stepwise fashion, until response is achieved) mini mizes the risk of GVHD. This approach is a safe first choice strategy for the majority of patients provided that enough time has elapsed to avoid the highest risk period for acute lifethreatening GVHD (~6-9 months post transplant 28, 29 ). Interestingly, although donor lymphocyte infusion is capable of eradicating detect able BCR-ABL1 transcripts in the majority of patients undergoing treatment for molecular relapse, BCR-ABL1 transcripts can subsequently be detected intermittently in many of these patients by sensitive PCR techniques, although progressive disease rarely develops in these cases 73 . This finding might reinforce the idea that, rather than totally eliminating the BCR-ABL1 clone, HSCT exerts a Tcell dependent immune control of the disease that results in effective cure.
TKIs have been used in the setting of postHSCT relapse, but it is likely that significant resistance or intolerance to TKI therapy will have developed before HSCT, given that most HSCT recipients have cycled through multiple TKIs, making their use less likely to be effective. In the case of relapse in TKInaive or TKI responsive patients, a trial or reintroduction of these agents might be beneficial. However for those patients relapsing early or with aggressive disease, rapid with drawal of existing immunosuppression, immune therapy with donor lympho cyte infusion and TKIs are unlikely to restore remission, and experimental agents offer the only prospect of survival.
Conclusions
For 30 years, HSCT for CML informed transplant prac tice for many haematological malignancies, and many of the lessons learned remain applicable to current practice. Following the success of the TKIs, however, HSCT has been increasingly reserved for highrisk patients with resistant and/or advanced disease, resulting in a steep decline in the number of HSCTs for patients with CML over the past 20 years (FIG. 2) . The use of TKIs undoubt edly constitutes a huge step forward in the management of CML, but not all patients will respond to, or can tol erate, these drugs. The apparent reluctance to perform HSCT means that, frequently, patients are referred for transplant after the disease has progressed beyond chronic phase, which consequently increases the com plexity and risks of the transplant. New tools for early assessment should help identify poor responders quickly, allowing them to rapidly cycle through the available TKIs and to be given the opportunity to undergo HSCT, particularly in light of the excellent outcome in studies carried out over the past 5-10 years.
When considering HSCT for CML, it is important to remember that a poor response to a TKI does not predict a poor response to transplant, because of the independ ent mechanisms of disease control -TKIs pharmaco logically block the activity of BCR-ABL1, whereas the benefit of HSCT is dependent on the GVL effect. For that reason, resistance to one or more TKI, whether in the presence of an identifiable tyrosine kinase domain mutation or not, should not influence transplant out come. HSCT should not be seen as a 'last ditch' or 'sal vage' option, but rather as a feasible treatment strategy to be considered early in the management plan of those patients with less than optimal responses to TKIs. The overwhelming data indicating that disease stage at time of transplant remains one of the strongest predic tors of transplant outcome, coupled with the findings that very early assessment can strongly predict inferior longterm outcome with TKIs, might prompt HSCT to be considered as a viable approach at an early time point in the disease course for some patients. The key issues for HSCT in CML are those of patient selection, risk stratification and outcome optimization by means of regimen selection and improved supportive care.
Several unanswered questions remain, however, particularly regarding the regimen choice, use of Tcell depletion and pretransplant optimization, but with the reduced numbers of patients undergoing HSCT, it seems unlikely that studies with sufficient power will exist to answer them. A wealth of existing data provides a firm base for the use of HSCT in CML, and the key message remains that transplantation is a viable treatment option that should not be delayed or overlooked. Whereas in the past the aim of CML physicians was to control the symptoms of the disease, the current goal is to normal ize the lifespan for these patients, and HSCT offers one route to achieve this aim.
